UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 28,587 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 12.2% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 205,760 shares of the company’s stock after selling 28,587 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Maravai LifeSciences were worth $1,710,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of MRVI. Blue Trust Inc. bought a new position in Maravai LifeSciences in the 2nd quarter valued at about $44,000. Bank of New York Mellon Corp raised its position in Maravai LifeSciences by 30.1% during the second quarter. Bank of New York Mellon Corp now owns 506,413 shares of the company’s stock valued at $3,626,000 after purchasing an additional 117,120 shares in the last quarter. Liontrust Investment Partners LLP lifted its stake in Maravai LifeSciences by 14.7% during the second quarter. Liontrust Investment Partners LLP now owns 43,845 shares of the company’s stock worth $314,000 after purchasing an additional 5,628 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Maravai LifeSciences by 32.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 25,450 shares of the company’s stock valued at $182,000 after purchasing an additional 6,212 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of Maravai LifeSciences by 62.4% in the 2nd quarter. Principal Financial Group Inc. now owns 666,187 shares of the company’s stock valued at $4,770,000 after purchasing an additional 255,990 shares during the last quarter. 50.25% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently weighed in on MRVI shares. Wells Fargo & Company started coverage on Maravai LifeSciences in a research report on Tuesday, August 27th. They set an “overweight” rating and a $10.00 price objective for the company. Royal Bank of Canada dropped their target price on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Robert W. Baird reduced their price target on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. Wolfe Research began coverage on shares of Maravai LifeSciences in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, William Blair restated a “market perform” rating on shares of Maravai LifeSciences in a research report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Maravai LifeSciences presently has a consensus rating of “Hold” and an average price target of $10.28.

Maravai LifeSciences Stock Down 1.6 %

Shares of NASDAQ MRVI opened at $5.58 on Tuesday. The company has a 50 day simple moving average of $6.47 and a 200 day simple moving average of $7.71. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. Maravai LifeSciences Holdings, Inc. has a 1 year low of $4.28 and a 1 year high of $11.56. The firm has a market cap of $1.41 billion, a PE ratio of -3.40 and a beta of -0.08.

Insider Buying and Selling at Maravai LifeSciences

In related news, insider Carl Hull acquired 175,000 shares of the stock in a transaction dated Monday, November 11th. The stock was bought at an average cost of $5.64 per share, for a total transaction of $987,000.00. Following the completion of the transaction, the insider now directly owns 175,000 shares of the company’s stock, valued at $987,000. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.63% of the company’s stock.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.